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Abstract
Chronic inflammation is suggested to be associated with specific cancer sites, including breast 
cancer. Recent research has focused on the roles of genes involved in the leukotriene/lipoxygenase 
and prostaglandin/cyclooxygenase pathways in breast cancer etiology. We hypothesized that genes 
in ALOX/COX pathways and CRP polymorphisms would be associated with breast cancer risk and 
mortality in our sample of Hispanic/Native American (NA) (1,430 cases, 1,599 controls) and non-
Hispanic white (NHW) (2,093 cases, 2,610 controls) women. A total of 104 Ancestral Informative 
Markers was used to distinguish European and NA ancestry. The adaptive rank truncated product 
(ARTP) method was used to determine the significance of associations for each gene and the 
inflammation pathway with breast cancer risk and by NA ancestry. Overall, the pathway was 
associated with breast cancer risk (PARTP =0.01). Two-way interactions with NA ancestry (padj< 
0.05) were observed for ALOX12 (rs2292350, rs2271316) and PTGS1 (rs10306194). We observed 
increases in breast cancer risk in stratified analyses by tertiles of polyunsaturated fat intake for 
ALOX12 polymorphisms; the largest increase in risk was among women in the highest tertile with 
ALOX12 rs9904779CC (Odds Ratio (OR), 1.49; 95% Confidence Interval (CI) 1.14–1.94, 
padj=0.01). In a sub-analysis stratified by NSAIDs use, two-way interactions with NSAIDs use 
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were found for ALOX12 rs9904779 (padj= 0.02), rs434473 (padj= 0.02), and rs1126667 (padj= 
0.01); ORs for ALOX12 polymorphisms ranged from 1.55–1.64 among regular users. Associations 
were not observed with breast cancer mortality. These findings could support advances in the 
discovery of new pathways related to inflammation for breast cancer treatment.
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Introduction
It has been suggested that chronic inflammation is associated with specific sites of cancer, 
including cancer of the liver and colon, and in more recent research, cancer of the breast [1]. 
The direct relationship between inflammation and cancer is broadly accepted; yet, many of 
the molecular and cellular mechanisms facilitating this relationship remain uncertain [1]. A 
number of inflammatory cells, oxidants, growth factors, cytokines, and proinflammatory 
lipid mediators have been identified as factors associated with chronic inflammation [2]. For 
example, arachidonic acid (AA), a polyunsaturated omega-6 fatty acid, when oxygenated is 
transformed into numerous products which mediate or modify inflammatory reactions [3]. 
Two critical pathways involved in modifying the inflammatory response are the leukotriene 
and prostaglandin pathways; both of these pathways use AA as their primary precursor [4]. 
In the leukotriene pathway, arachidonate lypoxygenases (ALOXs) convert AA into 
leukotrienes, a class of paracrine hormones included in the inflammatory response, as well 
as other inflammation-mediating eicosanoids which are suspected to be involved in several 
inflammatory diseases [4]. In the prostaglandin pathway, cellular cyclooxygenases (COX) 
convert AA into an intermediate prostaglandin, PG-G2. The metabolites of the prostaglandin 
pathway are produced in human tissues and regulate physiological processes including 
angiogenesis, coagulation, proliferation, immune response, and inflammation [5].
Specific genes involved in the leukotriene/lipoxygenase and prostaglandin/cyclooxygenase 
pathways have been implicated in carcinogenesis, and recent research has focused on the 
roles of these genes in breast cancer etiology. Arachidonate 12-lipoxygenase (ALOX12) has 
been described as pro-carcinogenic, as it converts AA to 12-hydroperoxyeicosatetraenoic 
acid (12-HPETE) and increases expression of proinflammatory cytokine genes, such as 
tumor necrosis factor-alpha [4,6], while ALOX15 has an anti-carcinogenic role, as it 
decreases cancer cell proliferation and increases apoptosis [4,7]. Very few studies to date 
have investigated the relationships of ALOX genes with breast cancer risk [8–10]. In a case-
control study of Indian women conducted by Prasad et al., the functional ALOX12 
polymorphism rs1126667 (Gln261Arg) was found to be significantly associated with an 
increase in breast cancer risk [odds ratio (OR) rs1126667AG/GG, 3.78; 95% confidence 
interval (CI) 2.37–6.04)] [10]. The study also revealed differences in genotype frequencies 
for rs1126667 among various racial/ethnic populations, suggesting that racial/ethnic 
differences in genotypes also may contribute to racial/ethnic differences in risk of breast 
cancer.
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Cyclooxygenase occurs in several isoforms, including COX-1 and COX-2. COX-1 is the key 
enzyme in prostaglandin synthesis, while COX-2 is unexpressed under normal conditions 
and up-regulated by cytokines, growth factors, and tumor promoters. COX-2 expression is 
increased in the earlier stages of carcinogenesis and tumor development or growth [11]. 
PTGIS, also known as prostacyclin synthase, is produced by cyclooxygenase and converts 
prostaglandin H2 to prostaglandin. Some studies have examined the associations between 
COX polymorphisms and breast cancer risk but findings have been inconsistent [11–15]. 
Abraham et al. [15] examined the associations between common polymorphisms in the 
prostaglandin pathway (including COX-1/2 and PTGIS) and breast cancer risk and survival; 
their results were not indicative of significant associations with COX-1 and COX-2 
polymorphisms and breast cancer risk or survival; but the homozygous variant genotype of 
PTGIS rs5602 did show a modest increase in breast cancer risk [15]. Although findings have 
been inconsistent, numerous epidemiologic studies have established that use of aspirin and 
nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the risk of breast cancer [16]. 
NSAIDs function by inhibiting COX genes, suggesting that the positive effect of NSAIDs in 
the reduction of breast cancer risk may be linked to suppression of COX overexpression 
[17].
Another marker of inflammation is C-reactive protein (CRP). CRP is an acute phase protein 
characterized by increases in its plasma concentration in response to acute inflammation, 
tissue damage, or infection. CRP has also been shown to be associated with chronic low-
grade inflammation in diseases such as diabetes, obesity, heart disease, and specific types of 
cancers [18]. The physiological role of circulating CRP has been investigated in several 
studies of breast cancer outcomes and survivorship [19–21]; however, few studies have 
examined the associations between genetic variation in the CRP gene and breast cancer risk 
[22] and to date, no published studies have investigated CRP genetic associations with 
breast cancer survival.
As previously mentioned, AA is a polyunsaturated omega-6 fatty acid involved in the 
leukotriene/lipoxygenase and prostaglandin/cyclooxygenase pathways. Both animal and 
human studies have indicated that high intakes of omega-polyunsaturated fatty acids 
(PUFAs), regulate various stages in the development of breast and colon cancer [23]. Case-
control studies have shown modest positive associations with high-fat diets and 
postmenopausal breast cancer risk, and strong correlations have been found between fat 
intake and breast cancer rates [23]. Previous studies suggest a role for dietary fats, such as 
polyunsaturated fats, as risk modifiers in breast cancer associations [23].
We hypothesized that polymorphisms in the ALOX12, ALOX15, CRP, PTGS1 (COX-1), 
PTGS2 (COX-2), and PTGIS genes would be associated with breast cancer risk and breast 
cancer-specific mortality in our sample of Hispanic and non-Hispanic white (NHW) women 
from the Breast Cancer Health Disparities Study (BCHDS). As a secondary aim, we 
evaluated the hypothesized associations between these genes and breast cancer risk by 
subgroups of Native American (NA) ancestry, menopausal status, body mass index (BMI), 
history of NSAIDs and aspirin use, and dietary fat intake.
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The BCHDS consists of participants from three population-based case-control studies: the 4-
Corners Breast Cancer Study (4-CBCS), the San Francisco Bay Area Breast Cancer Study 
(SFBCS), and the Mexico Breast Cancer Study (MBCS) [24]. All participants signed 
informed written consent prior to participation, completed an interview, and had a blood or 
mouth sample available for DNA extraction. The study was approved by the Institutional 
Review Board for Human Subjects at each institution.
The 4-CBCS participants were Hispanic, NA (non-reservation living), and NHW women 
between 25 and 79 years of age with a histological confirmed diagnosis of in situ or invasive 
cancer between October 1999 and May 2004; controls were selected from the target 
populations of cases living in Arizona, Colorado, New Mexico, and Utah and were 
frequency matched to cases on ethnicity and 5-year age distribution [25]. Only 2.5% of the 
total study population for the 4-CBCS was NA, therefore, these women were analyzed with 
Hispanic women. The SFBCS included Hispanic and NHW women aged 35 to 79 years 
from the San Francisco Bay Area diagnosed with a first primary histologically confirmed 
invasive breast cancer between April 1995 and April 2002; controls were identified by 
random-digit dialing and frequency-matched to cases based on the expected race/ethnicity 
and 5-year age distribution [26,27]. Participants from the MBCS were between 28 and 74 
years of age, living in one of three states, Monterrey, Veracruz and Mexico City, for the past 
five years. Participants from MBCS were not asked race or ethnicity. Eligible cases in 
Mexico were women diagnosed with either a new histologically confirmed in situ or 
invasive breast cancer between January 2004 and December 2007 at 12 participating 
hospitals from three main health care systems; controls were randomly selected from the 
catchment area of the 12 participating hospitals using a probabilistic multi-stage design [28].
Data Harmonization
Interview data were harmonized across the three studies [24]. The present analyses 
considered adjusting for BMI (kg/m2) calculated as self-reported weight during the referent 
year (or more distantly recalled weight if referent year weight was not available or measured 
weight if neither were available) divided by measured height squared, parity (number of live 
births and stillborn pregnancies), self-reported ethnicity in the U.S. studies (all women in 
Mexico were considered Hispanic in analysis focusing on ethnicity), and highest level of 
education. The referent year was defined as the calendar year prior to diagnosis for cases or 
selection into the study for controls.
Genetic Data
DNA extraction occurred from either whole blood (n=7,286) or mouthwash (n=637) 
samples. Whole Genome Amplification (WGA) was applied to the mouthwash-derived 
samples prior to genotyping. A tagSNP approach was used to characterize variation across 
candidate genes. TagSNPs were selected based on the following: linkage disequilibrium 
(LD) blocks were defined using a Caucasian LD map and an r2=0.8; minor allele frequency 
(MAF) >0.1; range= −1500 bps from the initiation codon to +1500 bps from the termination 
codon; and 1 SNP/LD bin. A total of 104 Ancestral Informative Markers (AIMs) was used 
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to distinguish European and NA ancestry in the study population [24]. All markers were 
genotyped using a multiplexed bead array assay format based on GoldenGate chemistry 
(Illumina, San Diego, California). A genotyping call rate of 99.93% was reached (99.65% 
for WGA samples). We included 132 internal replicates that were blinded representing 1.6% 
of the sample set. The duplicate concordance rate was 99.996% as determined by 193,297 
matching genotypes among sample pairs [24].
In the current analysis, we examined polymorphisms in the ALOX12 (n=6 single nucleotide 
polymorphisms (SNPs)), ALOX15 (n=5), CRP (n=3), PTGIS (n=2), PTGS1 (n=5), and 
PTGS2 (n=5) genes. Table 1 describes the 26 SNPs in detail, including the MAFs and 
adjusted Hardy-Weinberg equilibrium (HWE) p values.
Survival Data
Survival status was available for the Utah, New Mexico, Colorado, Arizona, and California 
study centers. Each center’s respective cancer registry provided information on date of death 
or last follow-up (month and year). Survival (in months) was calculated as the difference 
between diagnosis date and date of death or last follow-up. The cause of death was classified 
as breast cancer if either the primary or contributing cause of death noted on the death 
certificate was breast cancer. Survival data were not available for the MBCS.
Statistical Methods
STRUCTURE was used to compute individual ancestry assuming two founding populations 
[29,30] and each study participant was classified by level of percent NA ancestry. The 
following strata for percent NA ancestry were created using cut-points based on the 
distribution of NA ancestry in the control population: 0–28%, 29–70%, and 71–100%. The 
groups were categorized in this manner to ensure sufficient power to assess associations. For 
stratified analyses in the present analyses, two groups were used for comparisons: low NA 
ancestry: < 29% vs. high NA ancestry: ≥ 29%. When used as an adjusting variable to assess 
confounding, NA ancestry was modeled as a continuous variable.
Power calculations were performed utilizing online software, The Genetic Power Calculator, 
which is located at the following: http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html. This 
software is used for the analysis of discrete traits in case-control studies [31]. The following 
parameters were considered to estimate the power using the study-specific median 
MAF=0.23 of the polymorphisms combined (see Table 1): number of cases, ratio of controls 
to cases, prevalence of breast cancer in U.S. population based on SEER age-adjusted 
prevalence, genotype point estimate (2-degree of freedom test/co-dominant model), D 
prime/r2 (LD) =0.8, and defined type 1 error rate=0.05. Using the median MAF to detect an 
odds ratio (OR) of 1.20 and 1.50, under the above conditions, the overall power would be 
equal to 43% and 98%, respectively.
Descriptive statistics were calculated for all covariates and t-tests and chi-square tests were 
used to assess differences between groups. The homozygous common genotypes for each 
polymorphism were used as the referent categories. Using co-dominant models, genotype 
associations for all SNPs were estimated as ORs with 95% confidence intervals (CIs) by 
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unconditional logistic regression with adjustments for age, study center, and percent NA 
ancestry. Based on initial assessment of the co-dominant associations, dominant and 
recessive models were also examined. Potential confounders included BMI, menopausal 
status, parity, ethnicity, education, menopausal hormone therapy use, physical activity, 
caloric intake per day, and smoking status (ever or never). These covariates were included in 
multivariable models if their univariate P values were ≤ 0.20 and if they changed the point 
estimate for the main effects of the genotypes by ≥ 10% for SNPs that were found to be 
statistically significant prior to multiple comparisons [32]. However, there was no evidence 
of confounding and the models were adjusted for age, study center, and percentage of NA 
ancestry. Interactions between the pathway genes, NA ancestry, BMI (normal: < 25 kg/m2 
vs. overweight or obese: ≥ 25 kg/m2), menopausal status, and dietary fat intake were 
assessed using the likelihood-ratio test comparing the model including an interaction term 
with a reduced model without the term. A subset analysis (n= 3,771) was conducted to 
evaluate interactions between SNPs and history of regular NSAIDs and aspirin use using the 
4-CBCS sample, due to data not collected for these variables in the MBCS and the SFBCS. 
To account for the different number of foods queried on the diet questionnaires used for 
each study, dietary fat (total fat and polyunsaturated fat) intakes were evaluated as grams of 
fat per 1,000 calories and tertiles of intake based on the study-specific distribution of among 
controls.
For survival analyses, hazard ratios (HR) and 95% CIs were estimated using multivariable 
Cox proportional hazard models and were adjusted for SEER disease stage at diagnosis, age, 
NA ancestry, and study center. Stratified analyses were also conducted for survival analyses 
to determine if there was evidence of effect modification by NA ancestry.
Women were classified as either premenopausal or postmenopausal based on self-reported 
responses to questions on menstrual history. Women were classified postmenopausal using 
study-specific criteria. Those who were taking (HT) and still having periods and were at or 
above the 95th percentile of age for ethnicity of those who reported having a natural 
menopause among their study center, were classified as postmenopausal. This age was 58 
years for NHWs and 56 for Hispanics in the 4-CBCS, age 54 in the MBCS, and 55 for 
NHWs and 56 for Hispanics in the SFBCS.
Results were adjusted for multiple comparisons taking into account tagSNPs within each 
gene using the step-down Bonferroni correction (i.e., Holm’s method) based on the effective 
number of independent SNPs as determined using the SNP spectral decomposition method 
proposed by Nyholt [33] and modified by Li and Ji [34]. The interaction p values, based on 
1-df likelihood-ratio tests, were adjusted using the step-down Bonferroni correction or the 
Holm’s test [35]. We considered an adjusted p value < 0.05 as potentially important for main 
effects and for interactions. The adaptive rank truncated product (ARTP) method that uses a 
highly efficient permutation algorithm to determine the significance of association of each 
gene and of the inflammation pathway with breast cancer risk overall and by NA ancestry 
was also utilized. The gene p values were generated using the ARTP package in R, 
permuting outcome status 1,000 times while adjusting for age, study center, and NA 
ancestry [36]. We report both pathway and gene p values (PARTP). All other data analyses 
were performed using SAS version 9.3 (SAS Institute, Cary NC).
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The distributions of the demographic and major risk factors for breast cancer in the BCHDS 
have been previously reported [24,37]. A total of 7,732 breast cancer cases and controls 
were included in analyses that evaluated breast cancer risk. Table 2 describes the 
distribution of selected variables of importance to the present analysis. More Hispanic 
women were overweight or obese compared to NHW women, regardless of case-control 
status (p <0.001); however, NHW women consumed more dietary fats compared to Hispanic 
women in our study (p<0.001).
Associations of several of the genes with breast cancer risk were statistically significant both 
overall and by NA ancestry group as established by ARTP. For breast cancer risk among all 
women combined (Table 3), PARTP values were significant for the following genes: ALOX12 
(PARTP= 0.01), PTGS1 (PARTP= 0.01), and PTGS2 (PARTP= 0.01). When stratified by NA 
ancestry, ALOX12 was significantly associated with breast cancer risk among both the low 
(PARTP= 0.01) and high (PARTP= 0.01) ancestry groups. While ALOX15 (PARTP= 0.01) and 
PTGS1 (PARTP= 0.01) were significantly associated with breast cancer risk among women 
with low ancestry, PTGS2 was significantly associated with breast cancer risk among the 
high ancestry group (PARTP=0.03). Significant two-way interactions with NA ancestry (padj< 
0.05) were observed for ALOX12 polymorphisms (rs2292350, rs2271316) and for PTGS1 
(rs10306194). We did not find significant associations with CRP or PTGIS for breast cancer 
risk overall or by NA ancestry (data not shown). The overall pathway PARTP was 0.01.
Significant two-way interactions were observed between PTGS2 (rs20417) and menopausal 
status (padj= 0.02) and also between CRP (rs1130864) and BMI (padj= 0.02) (data not 
shown) for breast cancer risk. In analyses stratified by menopausal status, decreased breast 
cancer risk was associated with the CC vs. GG genotype of PTGS2 rs20417 among 
premenopausal women (OR, 0.60; 95% CI 0.37–0.99, padj=0.05). Decreased breast cancer 
risk also was associated with the CT/TT vs. CC genotype of CRP rs1130861 among women 
with normal BMI (OR, 0.79; 95% CI 0.67–0.93, padj=0.04).
Since dietary fat intake could modify breast cancer risk associated with leukotriene and 
prostaglandin pathway-related genes, we examined interaction effects between total dietary 
fat and polyunsaturated fat intakes. We did not observe significant two-way interactions 
between total fat and the ALOX, COX, or CRP genes; however, interactions were observed 
for ALOX12 polymorphisms rs434473 (padj=0.05) and rs1126667 (padj=0.05) (Table 4). 
Among women in the highest tertile of polyunsaturated fat intake, the largest increase in risk 
was observed for ALOX12 rs9904779CC (OR, 1.49; 95% CI 1.14–1.94, padj=0.01). No 
significant interactions were identified between polyunsaturated fat intake and ALOX15, 
COX, and CRP SNPs.
Table 5 shows genes with significant two-way interactions with regular use of NSAIDs for 
the 4-CBCS sample. Among regular users, statistically significant interactions were 
observed for ALOX12 polymorphisms rs9904779 (padj= 0.02), rs434473 (padj= 0.02), and 
rs1126667 (padj= 0.01). Significant ORs ranged from 1.55–1.64 among regular NSAIDs 
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users. We did not identify significant interactions for ALOX15, CRP, or the COX genes. No 
significant interactions were found with evaluation of regular aspirin use (data not shown).
Lastly, we examined the associations between the ALOX, CRP, and COX genes with risk of 
breast cancer-specific mortality for all invasive breast cancer cases and by NA ancestry. 
After adjustment for multiple comparisons, we did not find any of the polymorphisms to be 
associated with breast cancer mortality (data not shown).
Discussion
In this study, we observed that specific genes involved in the inflammation-related 
leukotriene/lipoxygenase and prostaglandin/cyclooxygenase pathways were significantly 
associated with breast cancer risk in our admixed population of Hispanic and NHW women. 
When stratified by level of NA ancestry, we found significant interactions among ALOX12 
SNPs (rs2292350, rs2271316) and PTGS1 rs10306194. Although we did not find significant 
interactions between total dietary fat intake and the inflammation genes, our results stratified 
by intake of polyunsaturated fat showed two-way interactions for ALOX12 polymorphisms 
rs434473 and rs1126667, and significant increases in breast cancer risk were observed 
among women with the highest tertile of polyunsaturated fat intake for three SNPs of 
ALOX12. In our subset analysis of the 4-CBCS, regular use of NSAIDs significantly 
interacted with ALOX12 polymorphisms (rs9904779, rs434473, rs1126667), with increases 
in breast cancer risk observed among regular users only. No significant interactions or 
associations were observed with regular aspirin use. We also considered the outcome of 
breast cancer-specific mortality, and no significant associations were identified for any of 
the genes.
The majority of associations were observed with ALOX12 polymorphisms. As previously 
mentioned, ALOX12 has been described as pro-carcinogenic, as it converts AA to 12-
HPETE and increases expression of proinflammatory cytokine genes, such as tumor necrosis 
factor-alpha [4,6]. Another ALOX12 product, 12-HETE, has also been found to be an 
eicosanoid that can stimulate cancer cells by up-regulating the expression and secretion of 
cathepsin B and by increasing the invasiveness and migration of cancer cells [8,38]; more 
specifically with breast cancer, 12-HETE has been found to increase proliferation and 
invasion of breast cells by inducing collagenase secretion from cells [39].
We also observed significant associations with overall breast cancer risk using ARTP for 
COX-1 and COX-2 genes; most of the associations were centered around PTGS1 
rs10306194 and PTGS2 rs5277. PTGS1 rs10306194 is located in the 3-prime UTR region, 
and PTGS2 rs5277, one of the most studied COX-2 variants, is located in a coding region. 
Findings of previous studies investigating PTGS1 and PTGS2 have been lacking; however, a 
recent meta-analysis examining the relationship between COX-2 SNPs and breast cancer risk 
only identified a borderline significant increased risk of breast cancer with rs5277 in a 
recessive model (OR, 1.22; 95% CI 0.96–1.55) [40]. Our results indicate that rs5277cc is 
associated with a reduced risk (OR, 0.64; 95% CI 0.44–0.94). Furthermore, in a report by 
Cox and colleagues, rs5275cc was found to be inversely associated with breast cancer risk 
among a sample of predominantly NHW women from the Nurses’ Health Study and the 
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Harvard Women’s Health Study (pooled OR, 0.80; 95% CI 0.66–0.97, p trend=0.02) [41]. 
Reportedly, rs5275 is in high LD with rs5277 and with the other highly known 
polymorphisms on PTGS2 [41,42]. Our findings for PTGS2 and breast cancer risk require 
replication in future studies and other potentially functional polymorphisms in the COX-2 
gene should be examined.
Use of NSAIDs has been associated with modest decreases in breast cancer risk in some 
epidemiological studies [43]. NSAIDs have an anti-inflammatory effect mainly because they 
bind with COX-2, and block the catalysis of AA to pro-inflammatory prostaglandins [44]. 
Several studies have examined the interaction between NSAIDs use and COX genes with 
breast cancer risk [12,44]; however, interaction effects between ALOX polymorphisms and 
NSAIDs use do not appear to have been investigated. Our results not only suggest that 
significant interactions exist between ALOX12 SNPs rs9904779, rs434473, and rs1126667, 
but that these specific SNPs significantly increase risk of breast cancer among regular 
NSAIDs users. Since the leukotriene and prostaglandin pathways are in competition, it has 
been speculated that ALOX polymorphisms might indirectly interact with NSAID use to 
modify the protective effect which could have pharmacogenetic repercussions for 
prescribing NSAIDs for long-term use in some individuals [4].
The study conducted by Prasad et al. revealed differences in genotype frequencies for 
ALOX12 rs1126667 among various racial/ethnic populations, including Indians, Caucasians, 
Chinese, Blacks, Koreans, and Spanish [10], suggesting that this polymorphism may 
contribute to racial/ethnic differences in breast cancer risk. Markers of inflammation, such 
as CRP levels, have also been found to be higher among minority populations, including 
Hispanics, when compared to individuals of European descent [45]. Although we did not 
observe associations between CRP variants and breast cancer risk overall or by NA ancestry, 
we found significant interactions with percent of NA ancestry and ALOX12 SNPs rs2292350 
and rs2271316. Most notably with PTGS1 rs10306194, we observed among women with 
high NA ancestry, a significant increase in breast cancer risk (OR, 1.45; 95% CI 1.23–1.70 
padj=0.0003) and a significant two-way interaction.
Certain breast cancer-related genes may modify the effects of hormonal risk factors, such as 
menopausal status, on breast cancer risk [46]. PTGS2 rs20417 significantly interacted with 
menopausal status and risk of breast cancer, and decreased risk of breast cancer was 
associated with the CC genotype among premenopausal women. In previous reports, ALOX 
genes have been found to be associated with the occurrence of natural menopause [47,48]. 
Xiao et al. identified several ALOX12 SNPs (rs2292350, rs312470, and rs312462) to be 
associated with age at natural menopause in postmenopausal women [47]. We did not 
observe any significant associations between ALOX12 or ALOX15 polymorphisms and 
breast cancer risk stratified by menopausal status.
The present analysis has several strengths and some limitations. Our study was able to 
compare breast cancer associations with 26 SNPs across six genes involved in several 
inflammation pathways and is the first to investigate associations of these specific 
inflammation genes and breast cancer risk by levels of NA ancestry. We were able to 
characterize the overall association of the combined pathway with breast cancer risk using 
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the ARTP method. Given the comprehensive data on lifestyle data, we were able to examine 
interaction effects between inflammation-related variables, including BMI and dietary 
polyunsaturated fat intake, and the genes. However, data for aspirin and NSAIDs use were 
not collected for Mexico and the SFBCS studies; but overall breast cancer risk estimates for 
the 4-CBCS were comparable to those for BCHDS. As with many epidemiologic studies, 
specific subject responses for variables included in subgroup analyses could be affected by 
recall bias. Our subgroup analyses and interactions should be examined further in future 
epidemiologic studies with larger sample sizes.
In summary, we observed significant associations between the ALOX12, PTGS1, and PTGS2 
genes and breast cancer risk; and overall, the inflammation-related pathway is significantly 
associated with breast cancer risk. Interestingly, many of the associations were with SNPs in 
ALOX12, and these were primarily observed among women who reported a history of 
regular NSAID use. We identified interactions with NA ancestry and dietary intake of 
polyunsaturated fats, and identified suggestive interactions between CRP and BMI and 
between PTGS2 and menopausal status. To the best of our knowledge, this is the first report 
to characterize the genetic variation of the ALOX genes and other specific genes involved in 
inflammation-related pathways using a tagSNP approach with breast cancer risk among an 
admixed population of women from the U.S. and Mexico. These findings could support 
advances in the discovery of new pathways related to inflammation for breast cancer 
treatment.
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